platoseedplatoseed
One-hour antibiotic sensitivity testing
Astek Diagnostics is building a platform (Eugris) that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. It is done by detecting the oxygen consumption of the bacteria
Astek Diagnostics offers a clinical diagnostics platform called JIDDU that provides infection confirmation for UTIs and antibiotic sensitivity indication within 1 hour, aiming to speed up and improve antibiotic choices. The company positions itself as reducing patient harm, costs, and antimicrobial resistance by delivering rapid, point-of-care guidance.
The JIDDU platform provides rapid UTI infection confirmation and antibiotic sensitivity indication within 1 hour at or near the point of care. It currently focuses on urine samples, with in-development expansion to CSF, effluent, and blood, enabling faster, more accurate antibiotic selection and reducing delays in treatment.
Who it’s for: Healthcare providers and facilities managing UTIs, including hospitals and rehabilitation centers, with a focus on rapid decision-making for antibiotic use and patient populations at risk for sepsis from UTIs.
mentions market entry planned for 2025, ongoing pilots with healthcare institutions
Mustafa Al-Adhami Ph.D., CEO, Astek Diagnostics. He has long experience in customer discovery and diagnostics. He envisioned the technology behind Eugris while completing his PhD. As a doctoral student, he won the national Three Minute Thesis (3mt) competition, Baylor Business Plan, elevator pitch competition, and VentureWell’s BMEidea competition. Mustafa has raised over $5M for Astek to date to revolutionize antibiotic prescription.
Formerly “Astek Diagnostics LLC”
AI enabling digital urine diagnostics in the home
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow
